Neoantigen × AI
Daily research signal
№44Brief

Geneos reports sustained PFS in two brain cancer patients

Today's brief is a single-item edition, but the signal earns the slot: Geneos Therapeutics announced a scientific meeting presentation of sustained immunosurveillance and progression-free survival in two brain cancer patients treated with its personalized neoantigen DNA immunotherapy.Morningstar

Brain tumors remain one of the hardest settings for immunotherapy, so even case-level durability data from a personalized vaccine platform is worth tracking for anyone underwriting the neoantigen space.

1new story
ClinicaltodayNew

Geneos Therapeutics Announces Scientific Meeting Presentation of Sustained Immunosurveillance and Progression-free Survival in Two Brain Cancer Patients Treated with Neoantigen Targeted Personalized DNA Immunotherapy - Morningstar

Geneos Therapeutics announced a scientific meeting presentation reporting sustained immunosurveillance and progression-free survival in two brain cancer patients treated with its neoantigen-targeted personalized DNA immunotherapy. The dataset is small — two patients, case-level — so this is an early clinical signal rather than pivotal evidence, but durability in CNS tumors is a meaningful proof point for a personalized vaccine modality. For investors, it is incremental validation of Geneos's DNA-based platform; the neoantigen targets at the core of such vaccines are selected computationally, so sustained immune monitoring also serves as an indirect read on target-selection quality. The announcement did not specify the meeting, trial, or tumor types beyond 'brain cancer.'

news · today · Morningstar